Mazdutide Tracker App
Master the IBI362 Research Phase
Get ready to track Mazdutide (IBI362) - the next-generation triple GIP/GLP-1/glucagon receptor agonist. Developed by Innovent Bioworks, Mazdutide is showing record-breaking potential in late-stage clinical trials.
What is Mazdutide?
Mazdutide (IBI362) is a potent oxyntomodulin analog being developed for obesity and type 2 diabetes. It is a triple agonist which means it simultaneously activates three key pathways: GLP-1, GIP, and Glucagon receptors.
This multi-pathway activation leads to enhanced weight loss results, improved metabolic health, and potentially superior fat-burning compared to single or dual agonists. In Phase 2 and 3 trials, Mazdutide has demonstrated significant reductions in body weight and liver fat content.
Shotlee provides the tools to log your research data, track dose escalation, and monitor results for Mazdutide and other advanced peptide therapies from day one.
Mazdutide FAQ
Is Mazdutide the same as Retatrutide?
Both are triple agonists (GLP-1/GIP/Glucagon), but Mazdutide (IBI362) is being developed by Innovent Bioworks while Retatrutide is an Eli Lilly compound. They are currently at different stages of clinical trials.
Can I track my Mazdutide injections in Shotlee?
Yes! Shotlee allows for custom medication logging, including Mazdutide, so you can track your doses, injection sites, and weight progress with precision.
What makes Mazdutide different from Mounjaro?
Mounjaro (Tirzepatide) is a dual agonist (GLP-1/GIP). Mazdutide adds a third mechanism—Glucagon receptor activation—which helps increase energy expenditure.